Data integrity has become one of the most discussed topics in pharmaceutical manufacturing. Organizations invest heavily in validated systems, audit trails, and compliance frameworks aligned with expectations from the U.S. Food and Drug Administration.
And yet, data integrity issues continue to appear.
This is not because systems are failing.
It is because organizations misunderstand where the real risk lives.
Data integrity is not fundamentally a system problem.
It is a behavior problem.
It exists in the moment an operator decides to record data later instead of immediately.
It exists when a value is adjusted without proper documentation.
It exists when pressure to meet timelines outweighs the discipline required to maintain accuracy.
Systems can record actions. They can create audit trails. They can enforce access controls.
But they cannot ensure intent.
That responsibility sits with people.
Organizations that struggle with data integrity often have strong technical controls but weak cultural alignment. Expectations are defined, but behaviors are inconsistent. Leadership emphasizes output, but not always accuracy.
And people respond accordingly.
To build true data integrity, organizations must go beyond systems.
They must:
- Reinforce expectations through leadership behavior
- Create accountability that is consistent and visible
- Align incentives with accuracy—not just speed
Because ultimately, data integrity is not about generating perfect data.
It is about generating data that can be trusted.
And trust is not built through systems.
It is built through behavior.
QxP Vice President Christine Feaster is a 20+ year veteran in pharma quality assurance. Prior to joining QxP, Christine was a vice president of U.S. Pharmacopeia.
